Company: ARTL
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001640334-25-002022
Chunk: 70

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 3
Chunk 70
---
licable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no sales of unregistered securities by us during the third quarter of 2025 that were not previously reported in our quarterly reports on Form 10-Q or current reports on Form 8-K filed with the SEC. 

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

Securities Trading Plans of Directors and Executive Officers

During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408. 

 34Table of Contents

Item 6. Exhibits

Exhibit No. Description3.1 Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Form 10-Q filed with the SEC on May 11, 2023)3.2 Certificate of Change (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on June 13, 2025)3.3 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on April 21, 2023)3.4Certificate of Amendment to Bylaws (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on September 10, 2025)4.1 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Form 8-K filed with the SEC on September 5, 2025)4.2 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Form 8-K filed with the SEC on October 1, 2025)10.1 At-The-Market Offering Agreement by and among the Artelo Biosciences, Inc. and R.F. Lafferty & Co., Inc., dated as of July 18, 2025 (incorporated by reference to Exhibit 1.1 of the Company’s Form